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Commentary 
IKI blockade as an antiarrhythmic mechanism 
The Controversy articles by Rees and Curtis’ I,, blockude is 
a potentially useful aiztiarrhythmic mechanism and Opthof ’ 
I,, blockade is unlikely to be u rrseful antiarrhythmic 
mechanism report conflicting views on the potential role of 
ZKI inhibition as an antiarrhythmic principle. Such articles 
stating different viewpoints are certainly of interest in the 
light of new strategies for antimhythmic drug development. 
Both articles comment on the role of the potassium current 
IKI for the resting membrane potential and the terminal phase 
of repolarisation. It is not so much the difference in opinion 
about the relative importance of these two effects for 
preventing or favouring arrhythmias but the entirely different 
philosophical approach which leads to the different 
conclusions. 
The article by Rees and Curtis starts from experimental 
observations in whole hearts showing that drugs which are 
considered as specific inhibitors of I,, lengthen the QT 
interval (increase of action potential duration) and prevent 
ischaemia induced arrhythmias in the rat. The speculation 
about the potential antiarrhythmic action is based on these 
two observations: refractory period prolongation is expected 
to decrease the probability of formation of re-entry, and 
consequently of arrhythmias. The authors are well aware of 
the potential pitfalls in their argument and carefully list the 
other known effects of the drug which are not related to IK,  
inhibition. The article by Opthof starts with the biophysical 
properties of the I,, channel. projects these properties into 
the role of I K j  in action potential generation. and finishes by 
rejecting the potential antiarrhythmic role of 1,’ inhibition. In 
particular, it is stated that inhibition of I K 1 ,  which flows close 
to resting potentials and is rectified at potentials remote from 
E,, is expected t o  shift resting membrane potential to more 
positive levels (depolarisation). Such a change is said to be 
proarrhythniic rather than antiarrhythmic. The effect of 
lengthening the terminal portion of the action potential. 
which is at the centre of the ReeslCurtis argument, is 
considered relatively unimportant. Opthof does not throw 
doubt on the observation that terikalant and its derivatives 
can be antiarrhythmic but attributes these effects to actions 
other than I,, blockade. 
The controversy raised by these two articles sheds some 
light on a situation which is inherent to arrhythmia research. 
On one hand, drugs are primarily developed in experimental 
systems which are reduced to single membrane channels. In 
such systems fascinating results on structure and function of 
membrane channels are obtained and drugs acting as specific 
inhibitors can be developed. On the other hand, the analysis 
of an antiarrhythmic effect necessarily has to involve whole 
tissue (cell cultures, isolated tissue, whole isolated or in situ 
hearts) because it is related to disturbances in impulse 
formation and impulse conduction. Such systems are 
indefinitely more complex and create a substantial likelihood 
of additional actions of a channel inhibiting drug. For 
example, this has been reported from ATP sensitive K’ 
channel inhibitors, which are known to have an important 
influence on glycolysis and lipid metabolism. Furthermore 
the fact that cardiac cells are coupled by proteins which may 
also be drug sensitive is rarely taken into account in 
antiarrhythmic principles. 
Personally, I consider the arguments in the article of Rees 
and Curtis, which is written with caution, to be correct as 
long as they are used to promote further research, which 
should include consideration of the pitfalls mentioned by 
Opthof. In particular, such drugs need to be tested for their 
effects on electrical cell to cell coupling and metabolism. 
Experiments have to be carried out at membrane, whole cell, 
tissue, whole heart, and animal levels, taking into account 
the advantages and limitations of each model as well as 
species differences. Only the combined interpretations of all 
results will eventually lead to a conclusive view. 
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Invited letter to the Editor 
Endothelium dependent relaxation in chronic heart 
failure 
The endothelium represents an important cell layer at the 
interface between the vessel wail and flow blood, subjected to 
physical forces and neurohumoral stimuli. Changes in blood 
flow result in adjustments of vessel diameter via vasoactive 
mechanisms triggered by physical forces. Chronic increases in 
flow are associated with enhanced release of endothelium 
dependent relaxing factor (EDRF)‘ and an increase in the 
vessel diameter.’ The latter appears to be an endothelium 
dependent response. Shear stress has been shown to be an 
important stimulus for the release of EDRF and more recently 
it has been demonstrated that increases in shear stress causes 
an upregulation of the expression of the endothelial nitric oxide 
synthase (cNOS).’ the enzyme which generates nitric oxide 
(NO) from its precursor L-arginine. Although NO may 
primarily account for the biological activity of EDRF, other 
factors may contribute to the dilator response of the vessel in 
response to increase flow. While the physiological role of 
bradykinin for the release of EDRF remains to be fully 
elucidated, bradykinin is a strong stimulus for the release of 
EDRF. The local concentration of bradykinin can be modulated 
by the tissue renin-angiotensin system, since the angiotensin 
converting enzyme degradates bradykinin. In the face of 
increased tissue ACE activity, one would expect lower local 
bradykinin levels.’ Conceivably, chronically reduced 
stimulation of release of EDRF (NO) may be associated with 
downregulation of the nitric oxide synthase. If this hypothesis 
is true, ACE inhibition should improve endothelial function by 
upregulating the cNOS. Indeed, preliminary data suggest that 
ACE inhibitor therapy improves endothelial dysfunction in the 
aorta of rats with myocardial infarction or aortic banding.6 
In a recent article by Buikema et a1 published in 
Cm-dimuscukir Research, endothelial dysfunction was 
demonstrated in the aorta proximal to banding whereas endo- 
thelial function was normal distal to banding. In rats with 
myocardial infarction, endothelial function was impaired in all 
segments of the aorta. The dilator effect of acetylcholine, an 
